WEX Pharmaceuticals Inc. is a publicly listed company (TSX:WXI) focused on the development and commercialization of innovative drug products, primarily for pain management.  WEX's lead compound, Tetrodotoxin, a sodium channel blocker, is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.